Pharmaceutical Product Monograph: Colistimethate Sodium (1 MIU, 2 MIU, 4.5 MIU)
In the pharmaceutical industry, Colistimethate Sodium (CMS) is a parenteral, cyclic polypeptide antibiotic belonging to the Polymyxin class. As a pharmacist and manufacturer, I view this molecule as the “Antibiotic of Last Resort”—it is technically designed to be an inactive “prodrug” that converts into Colistin within the body to combat Multi-Drug Resistant (MDR) Gram-negative “Superbugs.”
At your WHO-GMP facility in Mumbai, Colistimethate is a high-stakes Critical Care SKU. It is primarily reserved for ICU patients who have failed treatment with Carbapenems (like Meropenem) and are facing life-threatening infections.
Therapeutic Profile: Primary Indications
Colistimethate is indicated for severe infections caused by Gram-negative bacteria that are resistant to other antibiotic classes.
| Indication | Clinical Context | Technical Rationale |
| MDR Gram-Negative Sepsis | ICU / Critical Care | The Final Weapon: Targets Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. |
| VAP / HAP | Ventilator Infections | Used when pneumonia is caused by Carbapenem-Resistant Enterobacteriaceae (CRE). |
| Cystic Fibrosis (CF) | Inhalation Therapy | Technically administered via nebulizer to manage chronic Pseudomonas lung colonization. |
| Complicated UTI | Multi-drug Resistance | Used for severe kidney or bladder infections where no other oral or IV options remain. |
Mechanism: The “Detergent” Effect
Colistimethate works by physically dismantling the bacterial protective barrier:
LPS Binding: The positively charged Colistin molecule is attracted to the negatively charged Lipopolysaccharides (LPS) in the bacterial outer membrane.
Displacement of Ions: It displaces calcium and magnesium ions that stabilize the membrane.
Membrane Rupture: Technically, it acts like a detergent, puncturing holes in the cell membrane. This causes the internal contents of the bacteria to leak out, leading to rapid cell death.
The Pharmacist’s “Technical Warning”
The “Nephrotoxicity” Alert: As a pharmacist, I must emphasize that Colistimethate is highly Nephrotoxic (toxic to kidneys). Kidney function ($SCr$/$GFR$) must be monitored daily. Dose adjustments are technically mandatory for any degree of renal impairment.
Neurotoxicity: High doses can cause “pins and needles” (paresthesia), dizziness, and in severe cases, neuromuscular blockade, which can lead to respiratory arrest.
The “Prodrug” Conversion: Colistimethate is not active until it is converted to Colistin in the blood. This conversion is unpredictable, which is why “loading doses” are technically required to achieve therapeutic levels quickly in septic patients.
Mixing for Inhalation: If used in a nebulizer, the solution must be used immediately. Storing premixed Colistin for inhalation can lead to the formation of toxic byproducts that cause lung inflammation.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Unit” Precision (MIU): On your digital marketplace, clearly label your vials in International Units (IU) and milligrams (mg) of Colistin Base Activity (CBA). Note: 1 Million Units (1 MIU) is approximately equal to 34 mg of CBA. This clarity is a technical requirement for international B2B tenders.
The “Pyrogen-Free” Guarantee: Colistimethate is a complex polypeptide; your Depyrogenation Tunnel and endotoxin testing (LAL test) must be flawless, as this drug is injected into the most vulnerable, critically ill patients.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Colistimethate 1 MIU and 2 MIU vials to support your registration in international B2B tenders for “Last-Resort” anti-infectives.